Linomide-mediated protection of oligodendrocytes is associated with inhibition of nitric oxide production and IL-1β expression in Lewis rat glial cells

Neuroscience Letters

Volumn 249, Issue 1, 1998, Pages 17-20

  Xiao, Bao Guo ^a   Bail, Xue Fena ^a   Zhang, Guana Xian ^a   Hedlund, Gunnar ^b   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

Experimental allergic encephalomyelitis; Glia; Linomide; Multiple sclerosis; Nitric oxide

Indexed keywords

INTERLEUKIN 1BETA; NITRIC OXIDE; ROQUINIMEX;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CELL PROLIFERATION; CELL PROTECTION; GLIA CELL; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

EID: 0032511119     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00371-1     Document Type: Article

References (21)

1. Bai X.F., Shi F.D., Zhu J., Xiao B.G., Hedlund G., Link H. Linomide induced suppression of experimental autoimmune neuritis is associated witi downregulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
2. Da Cunha A., Vitkovie L. Simultaneous preparation of four type enriched glial cultures from rat cerebral cortex. J. Tiss. Cult. Meth. 13:1991;31-38.
3. de Wit R., Pawinsky A., Stoter G., van Oosterom A.T., Fossa S.D., Paridaens R., Svedberg A., de Mulder P.H. EORCT phase II study of daily oral Linomide in metastatic renal cell carcinoma patients with good prognostic factors. Eur. J. Cancer. 33:1997;493-495.
4. Hortelano S., Diaz-Guerra M.J.M., Gonzalez-Garcia A., Leonardo E., Gamallo C., Bosca L., Martinez-A C. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysacchride-activated macrophage and prevents nephritis in MRL/MD-Ipr/Ipr mice. J. Immunol. 158:1997;1402-1408.
5. Kalland T., Alm G., Stalhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J. Immunol. 134:1985;3956-3961.
6. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Kalland T., Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (auinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA. 90:1993;6400-6404.
7. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Ben-Nun A., Kalland T., Abramsky O. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann. Neurol. 34:1993;654-660.
8. Karussis D.M., Lehmann D., Brenner T., Wirguin I., Mizrachi-Koll R., Sicsic C., Abramsky O. Immunomodulation of experimental autoimmune myastheniz aravis with linomide. J. Neuroimmunol. 55:1994;187-193.
9. Karussis D.M., Meiner Z., Lehmann D., Gomori J., Schwarz A., Linde A., Abramsk O. Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: a double-blind, placebo-controlled pilot study witi monthly magnetic resonance imaging evaluation. Neurology. 47:1996;341-346.
10. Kim Y.S., Kim S.U. Oligodendroglial cell death induced by oxygen radical; and its Drotection bv catalase. J. Neurosci. Res. 29:1991;100-106.
11. Kleinau S., Larsson P., Bjork J., Holmdahl R., Klareskog L. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin. Exp. Immunol. 78:1989;138-142.
12. Lehmann D., Karussis D.M., Fluresco D., Mizrachi-Koll R., Ovadia H., Shezen E., Kalland T., Abramsky O. Immunomodulation of autoimmunity by Linomide inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 74:1997;102-110.
13. Lin R.F., Lin T.S., Tilton R.G., Cross A.H. Nitric oxide localized to spinal cords of mice with experimental allergic encephalomyelitis: an electron paramagnetic resonance study. J. Exp. Med. 178:1993;643-648.
14. Link, J. Interferon-y, interleukin-4 and transforming growth factor-(mRNA expression in multiple sclerosis and myasthenia gravis. Acta. Neurol. Scand., 90 (1994) Suppl 158 1-58.
15. Merril J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:1993;2132-2141.
16. Merrill J., Jondal M., Seeley J., Ullberg M., Siden A. Decreased NK killing in patients with MS: an analysis of the level of the single effector cell in periphera blood and cerebrospinal fluid in relation to the activity of the disease. Clin. Exp. Immunol. 47:1982;419-430.
17. Pawinski A., van Oosterom A.T., de Wit R., Fossa S., Croles J., Svedberg A., Lentz M.A., de Mulder P.H. An EORTC phase II study of the efficacy and safes, of Linomide in the treatment of advanced renal cell carcinoma. Eur. J. Cancer. 33:1997;496-499.
18. Rosenfeld C.S., Zeigler Z.R., Shadduck R.K., Nilsson B. Phase II study of roauinimex in myelodysplastic syndrome. Am. J Clin. Oncol. 20:1997;189-192.
19. Suzumura A., Mezitis S.G.E., Gonatas N.K., Siberberg D.H. MHC antiger expression on bulk isolated macrophage-microglia from newborn mouse brain induction of Ia antigen expression by y-interferon. J. Neuroimmunol. 15:1987;263-278.
20. Tyor W.R., Glass J.D., Griffin J.W., Becker P.S., McArthur J.C., Bezman L., Griffin D.E. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann. Neurol. 31:1992;349-360.
21. Zhang G.X., Yu L.Y., Shi F.D., Xiao B.G., Björk J., Hedlund G., Link H. Linomide supresses both Th1 and Th2 cytokines in experimental auto immune myasthenia gravis. J. Neuroimmunol. 73:1997;175-182.